Johnson & Johnson portfolio
Operating companyPortfolio as of Sep 30, 2026 (Q3 2026) · filed with the SEC on Oct 26, 2026 · data updated on Nov 6, 2026 · Q3 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Johnson & Johnson reported a $762M portfolio of 15 positions to the SEC as of the end of Q3 2026. Its largest positions are PTGX, NBTX, MGTX.
Sections with a free account
What changed this quarter
1 position with a change (1 added to). 1 is listed here: those of 0.5 points of the portfolio or more (up to 12).
- Cerebras Systems+140%more sharesIncreased1.5% → 3.0%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Protagonist TherapeuticsPTGX45.3%
- NanobiotixNBTX23.0%
- MeiraGTx HoldingsMGTX9.6%
- Rapport TherapeuticsRAPP7.9%
- Contineum TherapeuticsCTNM3.5%
- Cerebras SystemsCBRS3.0%
- XencorXNCR2.5%
- Legend BiotechLEGN2.1%
- FATE TherapeuticsFATE1.1%
- CVRxCVRX0.9%
- PROCEPT BioRoboticsPRCT0.9%
- Neumora TherapeuticsNMRA0.1%
- Vor BiopharmaVOR0.1%
- Standard BiotoolsLABunder 0.1%
- Adicet BioACETunder 0.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 97%
- ● Information Technology 3%
How its portfolio changed (8 quarters)
Q3 2026: 15
Q3 2026: 99%
Q3 2026: 0.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q4 2025 ↗filed Feb 13, 2026Amendment of Mar 18, 2026 (replaces the original) ↗
- 13F Q3 2025 ↗filed Nov 13, 2025Amendment of Mar 18, 2026 (replaces the original) ↗
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Operating company, per its SEC filings (EDGAR) (high confidence).
The data, as reported: EDGAR: SIC 2834 Pharmaceutical Preparations; since 2023-10-10 it has filed 10-K, 10-Q, 13F-HR, N-PX, SC 13G, SCHEDULE 13G (empresa operativa que cotiza)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: it is an operating company with strategic stakes, not an investment portfolio. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- South Street Advisors$769M
- Stanley Capital ManagementInvestment firm · $754M
- MacKay ShieldsInvestment firm · $745M
- Academy Capital Management$743M
- Southernsun Asset ManagementInvestment firm · $743M
- Newbrook Capital AdvisorsInvestment firm · $741M